Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 5 studies | 17% ± 1% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 20% ± 4% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 17% ± 1% | |
glutamatergic neuron | 3 studies | 22% ± 1% |
Insufficient scRNA-seq data for expression of NPRL2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 954.35 | 226 / 226 | 100% | 16.62 | 406 / 406 |
ovary | 100% | 1652.68 | 180 / 180 | 100% | 25.73 | 430 / 430 |
prostate | 100% | 1692.96 | 245 / 245 | 100% | 29.57 | 502 / 502 |
thymus | 100% | 1427.04 | 653 / 653 | 100% | 23.90 | 605 / 605 |
skin | 100% | 1047.03 | 1808 / 1809 | 100% | 20.96 | 472 / 472 |
lung | 100% | 1204.74 | 578 / 578 | 100% | 17.29 | 1154 / 1155 |
brain | 100% | 1495.35 | 2639 / 2642 | 100% | 28.02 | 705 / 705 |
uterus | 100% | 1468.84 | 170 / 170 | 100% | 21.96 | 458 / 459 |
breast | 100% | 1182.31 | 459 / 459 | 100% | 26.46 | 1114 / 1118 |
intestine | 100% | 1362.51 | 966 / 966 | 100% | 22.48 | 525 / 527 |
bladder | 100% | 1186.10 | 21 / 21 | 100% | 24.56 | 502 / 504 |
adrenal gland | 100% | 1223.53 | 258 / 258 | 100% | 24.02 | 229 / 230 |
esophagus | 100% | 1088.48 | 1445 / 1445 | 99% | 13.65 | 182 / 183 |
pancreas | 100% | 1487.24 | 328 / 328 | 99% | 18.32 | 177 / 178 |
kidney | 100% | 1226.74 | 89 / 89 | 99% | 16.05 | 895 / 901 |
stomach | 100% | 1184.69 | 359 / 359 | 99% | 20.61 | 284 / 286 |
adipose | 100% | 983.46 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 11.82 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 29.47 | 29 / 29 |
spleen | 100% | 1939.57 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 16.54 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 24.39 | 1 / 1 |
muscle | 100% | 1031.28 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1046.30 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 785.25 | 855 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 1100.61 | 913 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0033673 | Biological process | negative regulation of kinase activity |
GO_0010508 | Biological process | positive regulation of autophagy |
GO_1904262 | Biological process | negative regulation of TORC1 signaling |
GO_0034198 | Biological process | cellular response to amino acid starvation |
GO_1990130 | Cellular component | GATOR1 complex |
GO_0005774 | Cellular component | vacuolar membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0005515 | Molecular function | protein binding |
GO_0005096 | Molecular function | GTPase activator activity |
Gene name | NPRL2 |
Protein name | GATOR1 complex protein NPRL2 (Gene 21 protein) (G21 protein) (Nitrogen permease regulator 2-like protein) (NPR2-like protein) (Tumor suppressor candidate 4) NPR2 like, GATOR1 complex subunit |
Synonyms | TUSC4 |
Description | FUNCTION: Catalytic component of the GATOR1 complex, a multiprotein complex that functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway . In response to amino acid depletion, the GATOR1 complex has GTPase activating protein (GAP) activity and strongly increases GTP hydrolysis by RagA/RRAGA (or RagB/RRAGB) within heterodimeric Rag complexes, thereby turning them into their inactive GDP-bound form, releasing mTORC1 from lysosomal surface and inhibiting mTORC1 signaling . In the presence of abundant amino acids, the GATOR1 complex is ubiquitinated and inhibited by GATOR2 . Within the GATOR1 complex, NPRL2 constitutes the catalytic subunit that mediates the GTPase activator activity and under methionine-sufficient conditions, the GTPase activator activity is inhibited by PRMT1 through methylation and consequently inducing timely mTORC1 activation . .; FUNCTION: Suppresses Src-dependent tyrosine phosphorylation and activation of PDPK1 and its downstream signaling . Down-regulates PDPK1 kinase activity by interfering with tyrosine phosphorylation at 'Tyr-9', 'Tyr-373' and 'Tyr-376' residues . May act as a tumor suppressor . Suppresses cell growth and enhances sensitivity to various anticancer drugs . . |
Accessions | A0A590UJY0 ENST00000448302.1 ENST00000433999.5 F2Z2R8 Q8WTW4 ENST00000429366.5 ENST00000418825.5 ENST00000451194.5 ENST00000433381.5 F2Z3D4 ENST00000667046.1 ENST00000232501.8 [Q8WTW4-1] |